Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway

Journal of Immunology

Volumn 182, Issue 4, 2009, Pages 2532-2541

  Jacob, Noam ^a   Yang, Haitao ^a   Pricop, Luminita ^b   Liu, Yi ^b   Gao, Xiaoni ^b   Zheng, Song Guo ^a   Wang, Juhua ^a   Gao, Hua Xin ^c   Putterman, Chaim ^c   Koss, Michael N ^a   Stohl, William ^a   Jacob, Chaim O ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 17; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; ANTINUCLEAR ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNE DISEASE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; MALE; MEMORY T LYMPHOCYTE; MOUSE; NEPHRITIS; NEW ZEALAND BLACK MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; ANIMAL; BLOOD; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS NEPHRITIS; METABOLISM; MOUSE MUTANT; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIBODIES, ANTINUCLEAR; CD4-POSITIVE T-LYMPHOCYTES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; INTERLEUKIN-17; LUPUS NEPHRITIS; MICE; MICE, KNOCKOUT; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTE SUBSETS;

EID: 61449147025     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0802948     Document Type: Article

References (66)

1. Goeddel, D. V., B. B. Aggarwal, P. W. Gray, D. W. Leung, G. E. Nedwin, M. A. Palladino, J. S. Patton, D. Pennica, H. M Shepard, and B. J. Sugarman. 1986. Tumor necrosis factors: gene structure and biological activities. Cold Spring Harbor Symp. Quant. Biol. 51: 597-609.
2. Beutler, B., and A. Cerami. 1988. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu. Rev. Biochem. 57: 505-518.
3. Sugarman, B. J., B. B. Aggarwal, P. E. Hass, I. S. Figari, M. A. Palladino, and H. M. Shepard. 1985. Recombinant human tumor necrosis factor-α: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-945.
4. Kollias, G., and D. Kontoyianni. 2002. Role of TNF/TNFR in autoimmunity: specific TNF receptor blockade may be advantageous to anti-TNF treatments. Cytokine Growth Factor Rev. 13: 315-321.
5. Tartaglia, L. A., R. F. Weber, I. S. Figari, C. Reynolds, M. A. Palladino, and D. V. Goeddel. 1991. The two different receptors for tumor necrosis factor mediate distinct cellular responses. Proc. Natl. Acad. Sci. USA 88: 9292-9296.
6. Baud, V., and M. Karin. 2001. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol. 11: 372-377.
7. Tartaglia, L. A., D. V. Goeddel, C. Reynolds, I. S. Figari, R. F. Weber, B. M. Fendly, and M. A. Palladino. 1993. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J. Immunol. 151: 4637-4641.
8. Zheng, L., G. Fisher, R. E. Miller, J. Peschon, D. H. Lynch, and M. J. Lenardo. 1995. Induction of apoptosis in mature T cells by tumor necrosis factor. Nature 377: 348-351.
9. Elliott, M. J., R. N. Maini, M. Feldmann, J. R. Kalden, C. Antoni, J. S. Smolen, B. Leeb, F. C. Breedveld, J. D. Macfarlane, and H. Bijl. 1994. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 344: 1105-1110.
10. Van Dulleman, H. M., S. J. van Deventer, D. W. Hommes, H. A. Bijl, J. Jansen, G. N. Tytgat, and J. Woody. 1995. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroentrology 109: 129-135.
11. Karkar, A. M., Y. Koshino, S. J. Cashman, A. C. Dash, J. Bonnefoy, A. Meager, and A. J. Rees. 1992. Passive immunization against tumor necrosis factor-α (TNF-α) and IL-1β protects from LPS enhancing glomerular injury in nephrotoxic nephritis in rats. Clin. Exp. Immunol. 90: 312-318.
12. Ruddle, N. H., C. M. Bergman, K. M. McGrath, E. G. Lingenheld, M. L. Grunnet, S. J. Padula, and R. B. Clark. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172: 1193-2000.
13. Dick, A. D., P. G. McMenamin, H. Körner, B. J. Scallon, J. Ghrayeb, J. V. Forrester, and J. D. Sedgwick. 1996. Inhibition of tumor necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur. J. Immunol. 26: 1018-1025.
14. Jacob, C. O., S. Aiso, S. A. Michie, H. O. McDevitt, and H. Acha-Orbea. 1990. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-α and interleukin 1. Proc. Natl. Acad. Sci. USA 87: 968-972.
15. Yang, X. D., R. Tisch, S. M. Singer, Z. A. Cao, R. S. Liblau, R. D. Schreiber, and H. O. McDevitt. 1994. Effect of tumor necrosis factor α on insulin-dependent diabetes mellitus in NOD mice: the early development of autoimmunity and the diabetogenic process. J. Exp. Med. 180: 995-1004.
16. Grewal, I. S., K. D. Grewal, F. S. Wong, D. E. Picarella, C. A. Janeway, and R. A. Flavell. 1996. Local expression of transgene encoded TNF α in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells. J. Exp. Med. 184: 1963-1974.
17. Jacob, C. O., and H. O. McDevitt. 1988. Tumor necrosis factor-α in autoimmune 'lupus' nephritis. Nature 331: 356-358.
18. 1 mice. Clin. Immunol. Immunopathol. 52: 421-434.
19. 1 mice. J. Exp. Med. 179: 305-310.
20. Kontoyiannis, D., and G. Kollias. 2000. Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor. Eur. J. Immunol. 30: 2038-2047.
21. Feldmann, M., F. M. Brennan, and R. N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14: 397-440.
22. Sicotte, N. L., and R. R. Voskuhl. 2001. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology 57: 1885-1888.
23. Sandborn, W. J., and S. B. Hanauer. 1999. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm. Bowel Dis. 5: 119-133.
24. Van Oosten, B. W., F. Barkhof, L. Truyen, J. B. Boringa, F. W. Bertelsmann, B. M. von Blomberg, J. N. Woody, H. P. Hartung, and C. H. Polman. 1996. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47: 1531-1534.
25. Lenercept Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group. 1999. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53: 457-465.
26. Aringer, M., G. Steiner, W. B. Graninger, E. Höfler, C. W. Steiner, and J. S. Smolen. 2007. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis Rheum. 56: 274-279.
27. Aringer, M., and J. S. Smolen. 2008. The role of tumor necrosis factor-α in systemic lupus erythematosus. Arthritis Res. Ther. 10: 202-209.
28. Suvannavejh, G. C., H. O. Lee, J. Padilla, M. C. Dal Canto, T. A. Barrett, and S. D. Miller. 2000. Divergent roles for p55 and p75 tumor necrosis factor receptors in the pathogenesis of MOG(35-55)-induced experimental autoimmune encephalomyelitis. Cell. Immunol. 205: 24-33.
29. Kassiotis, G., and G. Kollias. 2001. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J. Exp. Med. 193: 427-434.
30. Vielhauer, V., G. Stavrakis, and T. N. Mayadas. 2005. Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. J. Clin. Invest. 115: 1199-1209.
31. Zhou, T., C. K. Edwards, P. Yang, Z. Wang, H. Bluethmann, and J. D. Mountz. 1996. Greatly accelerated lymphadenopathy and autoimmune disease in lpr mice lacking tumor necrosis factor receptor I. J. Immunol. 156: 2661-2665.
32. Waters, S. T., S. M. Fu, F. Gaskin, U. S. Deshmukh, S. S. Sung, C. C. Kannapell, K. S. Tung, S. B. McEwen, and M. McDuffie. 2001. NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci. Clin. Immunol. 100: 372-383.
33. Jacob, C. O., S. Zang, L. Li, V. Ciobanu, F. Quismorio, A. Mizutani, M. Satoh, and M. Koss. 2003. Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice. J. Immunol. 171: 1564-1571.
34. Jacob, C. O., L. Pricop, C. Putterman, M. N. Koss, Y. Liu, M. Kollaros, S. A. Bixler, C. M. Ambrose, M. L. Scott, and W. Stohl. 2006. Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF. J. Immunol. 177: 2671-2680.
35. Pfaffl, M. W. 2001. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29: e45.
36. Ebling, F. M., and B. H. Hahn. 1980. Restricted subpopulations of DNA antibodies in kidneys of mice with systemic lupus: comparison of antibodies in serum and renal eluates. Arthritis Rheum. 23: 392-403.
37. Boussiotis, V. A., L. M. Nadler, J. L. Strominger, and A. E. Goldfeld. 1994. Tumor necrosis factor α is an autocrine growth factor for normal human B cells. Proc. Natl. Acad. Sci. USA 91: 7007-7011.
38. Jacob, C. O., Z. Fronek, G. D. Lewis, M. Koo, J. A. Hansen, and H. O. McDevitt. 1990. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor α: relevance to genetic predisposition to systemic lupus erythematosus. Proc. Natl. Acad. Sci. USA 87: 1233-1237.
39. Tada, Y., A. Ho, S. Koarada, F. Morito, O. Ushiyama, N. Suzuki, Y. Kikuchi, A. Ohta, T. W. Mak, and K. Nagasawa. 2001. Collagen-induced arthritis in TNF receptor-1-deficient mice: TNF receptor-2 can modulate arthritis in the absence of TNF receptor-1. Clin. Immunol. 99: 325-333.
40. Luo, D., Y. Luo, Y. He, H. Zhang, R. Zhang, X. Li, W. L. Dobrucki, A. J. Sinusas, W. C. Sessa, and W. Min. 2006. Differential functions of tumor necrosis factor receptor 1 and 2 signaling in ischemia-mediated arteriogenesis and angiogenesis. Am. J. Pathol. 169: 1886-1898.
41. Rothe, M., S. C. Wong, W. J. Henzel, and D. V. Goeddel. 1994. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 78: 681-692.
42. Lin, J., D. Ziring, S. Desai, S. Kim, M. Wong, Y. Korin, J. Braun, E. Reed, D. Gjertson, and R. R. Singh. 2008. TNFα blockade in human diseases: an overview of efficacy and safety. Clin. Immunol. 126: 13-30.
43. Pasparakis, M., L. Alexopoulou, V. Episkopou, and G. Kollias. 1996. Immune and inflammatory responses in TNF α-deficient mice: a critical requirement for TNF α in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. J. Exp. Med. 184: 1397-1411.
44. Matsumoto, M., Y. X. Fu, H. Molina, and D. D. Chaplin. 1997. Lymphotoxin-α-deficient and TNF receptor-I-deficient mice define developmental and functional characteristics of germinal centers. Immunol. Rev. 156: 137-144.
45. Tkachuk, M., S. Bolliger, B. Ryffel, G. Pluschke, T. A. Banks, S. Herren, R. H. Gisler, and M. H. Kosco-Vilbois. 1998. Crucial role of tumor necrosis factor receptor 1 expression on nonhematopoietic cells for B cell localization within the splenic white pulp. J. Exp. Med. 187: 469-477.
46. + cells of older lupus mice. Eur. J. Immunol. 27: 1901-1910.
47. Lawson, B. R., R. Baccala, J. Song, M. Croft, D. H. Kono, and A. N. Theofilopoulos. 2004. Deficiency of the cyclin kinase inhibitor p21(WAF-1/CIP-1) promotes apoptosis of activated/memory T cells and inhibits spontaneous systemic autoimmunity. J. Exp. Med. 199: 547-557.
48. 1 mice: analysis of T-cell lymphokine synthesis. Immunology 85: 26-32.
49. Dauphinée, M. J., S. B. Kipper, D. Wofsy, and N. Talal. 1981. Interleukin 2 deficiency is a common feature of autoimmune mice. J. Immunol. 127: 2483-2487.
50. 1 mice. Lupus 4: 213-216.
51. 1 mice. Scand. J. Immunol. 42: 466-472.
52. Schorlemmer, H. U., G. Dickneite, E. J. Kanzy, and K. H. Enssle. 1995. Modulation of the immunoglobulin dysregulation in GVH and SLE-like diseases by IL-4 receptor. Inflamm. Res. 44: S194-196.
53. Erb, K. J., B. Rüger, M. von Brevern, B. Ryffel, A. Schimpl, and K. Rivett. 1997. Constitutive expression of interleukin (IL)-4 in vivo causes autoimmune-type disorders in mice. J. Exp. Med. 185: 329-339.
54. 1 lupus-like nephritis with monoclonal antibody to γ interferon. J. Exp. Med. 166: 798-802.
55. Ozmen, L., D. Roman, M. Fountoulakis, G. Schmid, B. Ryffel, and G. Garotta. 1995. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-γ receptor inhibits the onset of glomerulonephritis. Eur. J. Immunol. 25: 6-12.
56. 1 mice. J. Immunol. 160: 3713-3718.
57. Bettelli, E., T. Korn, and V. K. Kuchroo. 2007. Th17: the third member of the effector T cell trilogy. Curr. Opin. Immunol. 19: 652-657.
58. Langrish, C. L., Y. Chen, W. M. Blumenschein, J. Mattson, B. Basham, J. D. Sedgwick, T. McClanahan, R. A. Kastelein, and D. J. Cua. 2005. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201: 233-240.
59. Huang, F., C. Y. Kao, S. Wachi, P. Thai, J. Ryu, and R. Wu. 2007. Requirement for both JAK-mediated PI3K signaling and ACT1/TRAF6/TAK1-dependent NF-κB activation by IL-17A in enhancing cytokine expression in human airway epithelial cells. J. Immunol. 179: 6504-6513.
60. Nakae, S., Y. Iwakura., H. Suto, and S. J. Galli. 2007. Phenotypic differences between Th1 and Th17 cells and negative regulation of Th1 cell differentiation by IL-17. J. Leukocyte Biol. 81: 1258-1268.
61. Chen, Z., A. Laurence., and J. J. O'Shea. 2007. Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation. Semin. Immunol. 19: 400-408.
62. Stockinger, B., M. Veldhoen, and B. Martin. 2007. Th17 T cells: linking innate and adaptive immunity. Semin. Immunol. 19: 353-361.
63. + T helper cells. Cell 126: 1121-1133.
64. Sylvester, J., A. Liacini., W. Q. Li, and M. Zafarullah. 2004. Interleukin-17 signal transduction pathways implicated in inducing matrix metalloproteinase-3, -13 and aggrecanase-1 genes in articular chondrocytes. Cell. Signal. 16: 469-476.
65. Koenders, M. I., J. K. Kolls, B. Oppers-Walgreen, L. van den Bersselaar, L. A. Joosten, J. R. Schurr, P. Schwarzenberger, W. B. van den Berg, and E. Lubberts. 2005. Interleukin-17 receptor deficiency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3, 9, and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum. 52: 3239-3247.
66. Wong, C. K., L. C. Lit, L. S. Tam, E. K. Li, P. T. Wong, and C. W. Lam. 2008. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in autoimmunity. Clin. Immunol. 127: 385-393.